# DLPA_specsheet.md

## **DL-Phenylalanine (DLPA) Specification Sheet** 🧪

---

### **General Information**

| Property                  | Value                                      |
|---------------------------|--------------------------------------------|
| **Chemical Name**         | DL-Phenylalanine                           |
| **IUPAC Name**            | 2-Amino-3-phenylpropanoic acid             |
| **CAS Number**            | 150-30-1                                   |
| **Molecular Formula**     | C9H11NO2                                   |
| **Molecular Weight**      | 165.19 g/mol                               |
| **Chirality**             | 1:1 racemic mixture of D- and L-isomers    |
| **Solubility (H₂O)**      | Slightly soluble                           |
| **pKa**                   | 2.58 (COOH), 9.24 (NH2)                    |
| **Appearance**            | White crystalline powder                   |
| **Taste**                 | Slightly sweet and bitter                  |

---

### **Pharmacological Actions** ⚙️

| Isomer        | Activity                                                                 |
|---------------|--------------------------------------------------------------------------|
| **D-Phenylalanine** | Enkephalinase inhibitor → prolongs endogenous opioid action         |
| **L-Phenylalanine** | Precursor to L-Tyrosine → L-DOPA → Dopamine/Norepinephrine         |

---

### **Therapeutic Potential** 🩹

| Condition                   | Mechanism Involved                              |
|----------------------------|--------------------------------------------------|
| Chronic Pain               | Endorphin preservation (D-isomer)               |
| Depression                 | Dopamine/Norepinephrine support (L-isomer)      |
| Fibromyalgia               | Natural analgesia and mood enhancement          |
| ADHD                       | Cognitive support via catecholamine synthesis   |
| Opioid Withdrawal Support  | Mimics endogenous opioid tone without addiction |

---

### **Dosage Guidelines** 💊

| User Level      | Dosage Range              | Notes                                               |
|------------------|---------------------------|-----------------------------------------------------|
| General Support  | 500–1000 mg/day           | Best taken in 2 doses, AM and midday               |
| Pain Management  | 1000–2000 mg/day          | May stack with B6, ALCAR, or Tyrosine              |
| Cycling Protocol | 5 days on / 2 days off    | Optional – resets tolerance and balances enzymes   |

---

### **Legality Overview** ⚖️

| Region     | Status                          |
|------------|----------------------------------|
| USA        | Legal OTC supplement            |
| EU         | Legal in most countries         |
| Australia  | Unscheduled; legal as a supplement |
| UK         | Legal and widely available      |
| Asia       | Varies; typically unrestricted  |

---

### **Safety Profile** ✅

| Parameter              | Assessment                          |
|------------------------|--------------------------------------|
| **Addiction Risk**     | None                                 |
| **Tolerance**          | Minimal, may build with high doses   |
| **Drug Interactions**  | Caution with MAOIs, SSRIs, opioids   |
| **Pregnancy Category** | Not established – avoid unless advised |
| **Toxicity Level**     | Extremely low – GRAS status          |

---

### **Storage & Handling** 🧊

- Store in a cool, dry place below 25°C  
- Protect from light and moisture  
- Shelf life: 24–36 months sealed

---

### **Supplier Notes**

- DLPA should be >99% purity for therapeutic use  
- Certificate of Analysis (CoA) recommended for each batch  
- Vegan-friendly and non-GMO versions available

---

**Document Code**: DLPA-2025-SS-001  
**Last Updated**: May 2025  
**Prepared By**: NeuroOverride Research Group

---
